普健生物(武汉)科技有限公司

首页 产品目录 产品目录(简版) 公司动态 企业认证 企业体检 公司相册 联系我们

抗体:Anti-Semaglutide (GLP-1 analogue) Polyclonal antibody抗体,AntibodySystem Laboratories

发布人:普健生物(武汉)科技有限公司

发布日期:2024/5/16 16:06:53

标题:Anti-Semaglutide (GLP-1 analogue) Polyclonal antibody抗体,AntibodySystem Laboratories

链接:https://www.antibodysystem.com/product/17748.html

名称:Anti-Semaglutide (GLP-1 analogue) Polyclonal antibody抗体

别名:Sermaglutide, Semaglutide fandachem, Semaglutide impurity, Sermaglutide USP/EP/BP, semaglutide, Sermaglutide

货号:PHK13901

宿主:Rabbit

适用物种:Human

免疫原:Synthesized Semaglutide (GLP-1 analogue) conjugated with Carrier protein.

存储缓冲区:PBS, pH 7.4, containing 0.05% proclin 300, 50% glycerol.

形式:Liquid

浓度:1.28 mg/ml

克隆:Polyclonal

同型:IgG

应用:WB, IHC, ELISA

CAS910463-68-2

用途范围:仅用于科研

储存:Use a manual defrost freezer and avoid repeated freeze thaw cycles.Store at 4°C for frequent use.Store at -20 to -80 °C for twelve months from the date of receipt.

产品购买联系方式:027-65279366 /18162686757

邮箱:biolab-reagents@atagenix.com

QQ2663991332

 

参考文献:

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. PMID: 26308095

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. PMID: 33068776

GLP-1 receptor agonists and cardiovascular outcome trials: An update. PMID: 30528435

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. PMID: 38286487

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. PMID: 34911560

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). PMID: 30944040

Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. PMID: 34015974

Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. PMID: 32910487

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. PMID: 38316982

Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. PMID: 38079178

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. PMID: 32987188

The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. PMID: 37684186

Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. PMID: 29915923

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. PMID: 37952217

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. PMID: 37796527

Semaglutide (Ozempic) for weight loss. PMID: 33830968

Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. PMID: 31612934

Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. PMID: 37280458

Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? PMID: 30156747

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. PMID: 35838946

Liraglutide and obesity: a review of the data so far. PMID: 25848222

Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure. PMID: 37409733

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. PMID: 28266779

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). PMID: 38087976

GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity. PMID: 38060218

GLP-1 as a target for therapeutic intervention. PMID: 27591964

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. PMID: 37952131

Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. PMID: 31436480

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. PMID: 17098089

GLP-1 analogue therapy for obesity in people from Asia. PMID: 38330985

The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia. PMID: 35080714

Efficacy and safety of semaglutide for weight management: evidence from the STEP program. PMID: 36691309

The Future of the GLP-1 Receptor Agonists. PMID: 30903797

相关新闻资讯

Latikafusp抗体|Latikafusp(AMG 256)|PD-1抗体IL-21突变蛋白|佰乐博生物代理AntibodySystem

2024/06/07

Latikafusp抗体|Latikafusp(AMG 256)|PD-1抗体IL-21突变蛋白|佰乐博生物代理AntibodySystem Latikafusp (AMG 256)是一种双功能融合蛋白,包含靶向PD-1的抗体和IL-21突变蛋白,旨在向PD-1+细胞提供IL-21通路刺激。Latikafusp可以启动和延长细胞毒性和记忆T细胞的活性,并诱导抗肿瘤免疫。Latikafusp具

磷酸钠协同转运蛋白SLC34A2多克隆抗体,特异性高

2024/06/04

磷酸钠协同转运蛋白SLC34A2多克隆抗体,特异性高 佰乐博生物:佰乐博生物代理Antibodysystem,ProteoGenix品牌,是亚洲区运营总代理商 链接:https://www.antibodysystem.com/index/search?wd=SLC34A2 名称:磷酸钠协同转运蛋白SLC34A2多克隆抗体 别名:Sodium/phosphate cotr

佰乐博生物代理AntibodySystem,Recombinant Human SLC34A2/NaPi2b Protein, N-GST蛋白抗体

2024/06/04

佰乐博生物代理AntibodySystem,Recombinant Human SLC34A2/NaPi2b Protein, N-GST蛋白抗体 链接:https://www.antibodysystem.com/product/11408.html 名称:Recombinant Human SLC34A2/NaPi2b Protein, N-GST蛋白抗体 别名:Sodium